Figure 5:

Oxamate enhances the efficacy of BETi in preventing MOLM-13 chimerism in CDX. (A) NSGS mice were engrafted with MOLM-13 cells and treated with vehicle control, BETi (50 mg/kg), and/or oxamate (200 mg/kg), and then sacrificed. (B) Spleens were weighed and (C) tumor burden assessed by chimerism analysis by quantifying hCD45⁺hCD33⁺ cells using flow cytometry and (D) immunohistochemistry (hCD45, scale bar = 50 μm). (B-C) Each point represents a single mouse (mock, n = 9; BETi or oxamate, n = 10; BETi+oxamate, n = 11). (B) One- or (C) two-way ANOVA with Tukey multiple comparisons test (*P ≤ 0.05, ***P ≤ 0.001, ****P ≤ 0.0001, ns = not significant).